Inclisiran is an RNAi therapeutic that utilizes Alnylam Pharmaceuticals’ proprietary Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA conjugate delivery platform. It is currently being developed to lower the synthesis of PCSK9 levels and reduce LDL-C levels.
For information on ongoing clinical trials click .
The above investigational agent is not approved for commercial use in any market; the safety and efficacy of this investigational agent has not been evaluated by any regulatory authority for the uses described.
Global Medical Information
The Global Health Science Center (GHSC) Medical Professionals are available to answer your medical information requests, or receive adverse event reports, other safety related information, and product complaints.
Please click below to the Global Health Science Center.
Alternatively, adverse events may be reported to the FDA MedWatch Reporting System by phone at 1 800 FDA 1088 (1 800 332 1088) or by mail using Form FDA 3500 at